- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00376090
Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
13. oktober 2017 oppdatert av: U.S. Army Medical Research and Development Command
A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults
The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR.
This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
48
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Maryland
-
Rockville, Maryland, Forente stater, 20850
- US Military HIV Research Program
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 40 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
A participant must meet all of the following criteria:
- Low risk for HIV infection
- 18 to 40 years at the time of enrollment and vaccinia naive
- Good health
- Availability for 12 months of participation.
- Successful completion of the Test of Understanding
- Able and willing to give informed consent.
- HEMATOCRIT: WOMEN: 35 %-45 %; MEN 36 % - 49 %
- White cell count: 3,000 - 11,000 cells/mm3
- Platelets: 125,000 - 450,000 per mm3
- Normal cardiac enzyme level at second Screening Visit
- Urinalysis (UA) for protein and blood: negative or trace.
- Normal liver function tests to include ALT/AST, alkaline phosphatase, GGT (< 1.25x institutional upper limits of normal) and CPK (< 480) and creatinine (< 1.25 mg/dL)
- Negative serology for HIV infection
- Any female volunteer must have a negative serum or urine pregnancy test at the screening visit as well as immediately prior to each vaccine/placebo vaccination, as well as verbal assurance that adequate birth control measures have been followed for 60 days prior to the first vaccine/placebo vaccination and will continue to be followed for at least 3months after the final vaccine/placebo vaccination. This means using any of the following methods: Birth control drugs that prevent pregnancy given by pills, shots or placed under the skin, Male or female condoms with or without a cream or gel that kills sperm, diaphragm or cervical cap with a cream or gel that kills sperm, or Abstinence
Exclusion Criteria:
A volunteer will be excluded if one or more of the following conditions apply.
A woman who:
- Is pregnant.
- Is breast-feeding.
Anyone who:
- Is U.S. military personnel.
- Acknowledges engaging in highest-risk behavior within six months of study entry
- Has active tuberculosis or other systemic infectious process by review of systems and physical examination.
- Has history of or known cardiac disease including any of the following: prior myocardial infarction (heart attack), angina pectoris, congestive heart failure, conduction disturbances, repolarization (ST segment or T wave) abnormalities, serious cardiac arrhythmias (ventricular tachycardia or ventricular fibrillation), cardiomyopathy, pericarditis, stroke or transient ischemic attack, chest pain or shortness of breath with activity (e.g. climbing stairs), valvular heart disease including mitral valve prolapse, or other heart conditions under the care of a doctor.
- Has ECG on Screening Visit 2 with clinical significant findings, or features that would interfere with the assessment of myo/pericarditis (as determined by the contract ECG Lab) including any of the following: conduction disturbance (atrioventricular or intraventricular condition, left or right bundle branch block, AB block of any degree or QTc prolongation), repolarization (ST segment or T wave) abnormality, significant atrial or ventricular arrhythmia, frequent atrial or ventricular ectopy (e.g. frequent premature atrial contractions, 2 premature ventricular contractions in a row), ST elevation consistent with ischemia, or evidence of past or evolving myocardial infarction
- Has history of seizure disorder, immunodeficiency, chronic illness, autoimmune disease, diabetes mellitus active malignancy or use of immunosuppressive medications.
- Has evidence of psychiatric, medical and/or substance abuse problems during the past six months that the investigator believes would adversely affect the volunteer's ability to participate in the trial.
- Has occupational or other responsibilities that would prevent completion of participation in the study.
- Has received any live attenuated vaccine within 60 days of study entry.
- Has used experimental therapeutic agents within 30 days of study entry.
- Has received blood products or immunoglobulins in the past three months.
- Has history of anaphylaxis or other serious adverse reactions to vaccines.
- Has previously received an HIV vaccine or an MVA or vaccinia vaccine.
- Has chronic or active Hepatitis B or Hepatitis C virus infection or active syphilis (positive RPR and FTA).
- Has had an immediate type hypersensitivity reaction to eggs, egg products or neomycin/streptomycin (used to prepare MVA vaccine).
- Is a study site employee.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Group I Vaccine
|
10^7 PFU IM, 1.0 mL
10^6 PFU ID, 0.1 mL
10^8 PFU IM, 1.0 mL
10^7 PFD ID, 0.1 mL
|
Placebo komparator: Group I Placebo
|
1.0 mL IM
0.1 mL ID
|
Eksperimentell: Group II Vaccine
|
10^7 PFU IM, 1.0 mL
10^6 PFU ID, 0.1 mL
10^8 PFU IM, 1.0 mL
10^7 PFD ID, 0.1 mL
|
Placebo komparator: Group II Placebo
|
1.0 mL IM
0.1 mL ID
|
Eksperimentell: Group III Vaccine
|
10^7 PFU IM, 1.0 mL
10^6 PFU ID, 0.1 mL
10^8 PFU IM, 1.0 mL
10^7 PFD ID, 0.1 mL
|
Placebo komparator: Group III Placebo
|
1.0 mL IM
0.1 mL ID
|
Eksperimentell: Group IV Vaccine
|
10^7 PFU IM, 1.0 mL
10^6 PFU ID, 0.1 mL
10^8 PFU IM, 1.0 mL
10^7 PFD ID, 0.1 mL
|
Placebo komparator: Group IV Placebo
|
1.0 mL IM
0.1 mL ID
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety and Tolerability
Tidsramme: Study Day 0 through 8 months post-vaccination
|
Evaluate the safety and tolerability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) administered by IM or ID injection to HIV uninfected adults
|
Study Day 0 through 8 months post-vaccination
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity
Tidsramme: Study Day 0 through Study Day 280
|
Evaluate the ability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) to induce HIV antigen specific cellular and humoral immune responses
|
Study Day 0 through Study Day 280
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Mary Marovich, MD, DTM&H, US Military HIV Research Program
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juli 2005
Primær fullføring (Faktiske)
1. desember 2008
Studiet fullført (Faktiske)
1. desember 2008
Datoer for studieregistrering
Først innsendt
13. september 2006
Først innsendt som oppfylte QC-kriteriene
13. september 2006
Først lagt ut (Anslag)
14. september 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. oktober 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. oktober 2017
Sist bekreftet
1. oktober 2017
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RV 158
- A-12403 (Annen identifikator: USAMRMC HSRRB)
- WRAIR 1143 (Annen identifikator: WRAIR HURC)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
University of Colorado, DenverUniversity of IowaFullførtHealth Care Associated Infection | HåndhygieneForente stater
Kliniske studier på MVA-CMDR
-
Henry M. Jackson Foundation for the Advancement...Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... og andre samarbeidspartnereAktiv, ikke rekrutterende
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRPFullført
-
Instituto Nacional de Saúde, MozambiqueEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Swedish...Fullført
-
University of OxfordFullført
-
Fudan UniversityRekruttering
-
Università degli Studi dell'InsubriaFullførtLungekreft | Kirurgi - komplikasjoner | Moral
-
Bavarian NordicFullførtRespiratoriske syncytiale virusinfeksjonerForente stater
-
Hospital General Universitario de ValenciaUkjentPostoperative komplikasjoner | Lungekreft | Lungeskade | Lungeneoplasma | Thoracic | Voksen ALLE | Lungebetennelse | Lungeiskemi/hypoksi | Postoperativ respiratorisk komplikasjonSpania
-
University Hospital of FerraraFullført